Healthcare Implementation Communique (SUT) updated in Turkey in June 2022

On June 06, 2022, the Reimbursement Commission of the Social Security Institution (SSI) released an updated version of the Healthcare Implementation Communique (SUT). The main changes relate to the increase in reimbursement fees of genetic tests by approximately 10%.

Furthermore, 138 new tests have been added. New IVD tests belong to the following chapters: molecular microbiology (25 new tests); molecular cytogenetic tests (81 tests); molecular genetic tests (21 tests); oncological molecular tests (11 tests) (these chapters can be found in Annexes 2B and 2A-2 of the SUT). Some examples of the newly-introduced tests are listed below:

• 908122 “Clostridium difficile PCR” with the reimbursement tariff of 152 TRY
• 908141 “CMV drug resistance” with the reimbursement tariff of 1,059 TRY
• 908142 “Cryptosporidium PCR” with the reimbursement tariff of 152 TRY
• 908143 “EBV PCR” with the reimbursement tariff of 152 TRY
• 908337 “Meningitis Panel (CSF)” with the reimbursement tariff of 720 TRY
• 908338 “Respiratory system infection panel” with the reimbursement tariff of 720 TRY
• 908339 “Real-time PCR” with the reimbursement tariff of 152 TRY
• G100265 “FISH, MYC/IGH gene fusion” with the reimbursement tariff of 226 TRY
• G100266 “FISH, MYCN (2p24)/AFF3 (2q11)” with the reimbursement tariff of 226 TRY
• G100267 “FISH, NTRK1” with the reimbursement tariff of 226 TRY
• G101131 “Congenital Myasthenia Panel (16-40 genes)” with the reimbursement tariff of 1,629 TRY
• G101132 “Congenital Neutropenia Panel (5-15 genes)” with the reimbursement tariff of 821 TRY
• G101133 “Congenital Thrombocytopenia Panel (16-40 genes)” with the reimbursement tariff of 1,629 TRY
• G101211 “MODY Panel (10-20 genes)” with the reimbursement tariff of 1,165 TRY
• G101541 “Autoinflammatory Diseases Panel (5-15 genes)” with the reimbursement tariff of 821 TRY
• G101943 “IGL clonality test” with the reimbursement tariff of 293 TRY
• G101951 “KRAS gene sequence analysis” with the reimbursement tariff of 549 TRY
• G101952 “NRAS mutation analysis” with the reimbursement tariff of 293 TRY

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).